We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Medtronic (MDT - Free Report) closed at $100.72, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.23%. Meanwhile, the Dow experienced a drop of 1.11%, and the technology-dominated Nasdaq saw an increase of 0.42%.
The stock of medical device company has risen by 8.13% in the past month, leading the Medical sector's gain of 4.66% and the S&P 500's loss of 4.04%.
Market participants will be closely following the financial results of Medtronic in its upcoming release. The company plans to announce its earnings on November 24, 2026. The company's upcoming EPS is projected at $1.34, signifying a 1.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.46 billion, showing a 5.62% escalation compared to the year-ago quarter.
MDT's full-year Zacks Consensus Estimates are calling for earnings of $5.98 per share and revenue of $39.02 billion. These results would represent year-over-year changes of +8.14% and +7.31%, respectively.
Investors should also note any recent changes to analyst estimates for Medtronic. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
Investors should also note Medtronic's current valuation metrics, including its Forward P/E ratio of 17.12. Its industry sports an average Forward P/E of 19.71, so one might conclude that Medtronic is trading at a discount comparatively.
Investors should also note that MDT has a PEG ratio of 2.39 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.18.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Medtronic (MDT) Declines More Than Market: Some Information for Investors
In the latest trading session, Medtronic (MDT - Free Report) closed at $100.72, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.23%. Meanwhile, the Dow experienced a drop of 1.11%, and the technology-dominated Nasdaq saw an increase of 0.42%.
The stock of medical device company has risen by 8.13% in the past month, leading the Medical sector's gain of 4.66% and the S&P 500's loss of 4.04%.
Market participants will be closely following the financial results of Medtronic in its upcoming release. The company plans to announce its earnings on November 24, 2026. The company's upcoming EPS is projected at $1.34, signifying a 1.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.46 billion, showing a 5.62% escalation compared to the year-ago quarter.
MDT's full-year Zacks Consensus Estimates are calling for earnings of $5.98 per share and revenue of $39.02 billion. These results would represent year-over-year changes of +8.14% and +7.31%, respectively.
Investors should also note any recent changes to analyst estimates for Medtronic. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
Investors should also note Medtronic's current valuation metrics, including its Forward P/E ratio of 17.12. Its industry sports an average Forward P/E of 19.71, so one might conclude that Medtronic is trading at a discount comparatively.
Investors should also note that MDT has a PEG ratio of 2.39 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.18.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.